Compare Davita Inc (DVA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nomura Holdings Inc — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Nomura Holdings Inc trades at $10.02 (market cap $28.06B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.32% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NMR | |
|---|---|---|
Market Cap | $14.92B | $28.06B |
Sector | Health | Financials |
52-Week High | $235.71 | $9.75 |
52-Week Low | $103.87 | $6.30 |
Enterprise Value | $27.47B | — |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Nomura Holdings (NMR) trades at $9.62, down 0.41% on the day, with a P/E of 13.08 suggesting reasonable valuation. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Recent earnings show mixed results with one beat and two misses, but annual revenue grew to $1.66 trillion with a robust 20.49% net margin. The company posted record annual profit of $340.74 billion in 2025, driving positive sentiment around its wholesale and wealth management segments.
Nomura presents a compelling value opportunity with strong profitability metrics and expansion in core businesses, though recent earnings misses and negative operating cash flow pose near-term concerns. The bullish analyst consensus and technical setup support upside potential, but investors should monitor integration costs from recent acquisitions and debt levels that have increased to 26.25% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
